Carna Biosciences, Inc.
4572.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | ¥5,373 | ¥8,770 | ¥7,081 | ¥13,990 |
| - Cash | ¥2,108 | ¥2,889 | ¥3,379 | ¥3,818 |
| + Debt | ¥61 | ¥183 | ¥300 | ¥540 |
| Enterprise Value | ¥3,326 | ¥6,064 | ¥4,002 | ¥10,713 |
| Revenue | ¥636 | ¥1,626 | ¥1,387 | ¥2,018 |
| % Growth | -60.9% | 17.2% | -31.3% | – |
| Gross Profit | ¥466 | ¥1,451 | ¥1,215 | ¥1,882 |
| % Margin | 73.2% | 89.2% | 87.6% | 93.3% |
| EBITDA | -¥2,140 | -¥1,092 | -¥1,284 | -¥509 |
| % Margin | -336.3% | -67.1% | -92.6% | -25.2% |
| Net Income | -¥2,179 | -¥1,153 | -¥1,350 | -¥534 |
| % Margin | -342.4% | -70.9% | -97.3% | -26.5% |
| EPS Diluted | -121.64 | -68.62 | -99.1 | -42.1 |
| % Growth | -77.3% | 30.8% | -135.4% | – |
| Operating Cash Flow | -¥1,375 | -¥1,677 | -¥708 | -¥1,537 |
| Capital Expenditures | -¥13 | -¥12 | -¥126 | -¥42 |
| Free Cash Flow | -¥1,388 | -¥1,689 | -¥834 | -¥1,578 |